TY  - JOUR
A1  - Edgecock, T. R.
A1  - Caretta, O.
A1  - Davenne, T.
A1  - Densam, C.
A1  - Fitton, M.
A1  - Kelliher, D.
A1  - Loveridge, P.
A1  - Machida, S.
A1  - Prior, C.
A1  - Rogers, C.
A1  - Rooney, M.
A1  - Thomason, J.
A1  - Wilcox, D.
A1  - Wildner, E.
A1  - Efthymiopoulos, I.
A1  - Garoby, R.
A1  - Gilardoni, S.
A1  - Hansen, C.
A1  - Benedetto, E.
A1  - Jensen, E.
A1  - Kosmicki, A.
A1  - Martini, M.
A1  - Osborne, J.
A1  - Prior, G.
A1  - Stora, T.
A1  - Melo Mendonca, T.
A1  - Vlachoudis, V.
A1  - Waaijer, C.
A1  - Cupial, P.
A1  - Chancé, A.
A1  - Longhin, A.
A1  - Payet, J.
A1  - Zito, M.
A1  - Baussan, E.
A1  - Bobeth, C.
A1  - Bouquerel, E.
A1  - Dracos, M.
A1  - Gaudiot, G.
A1  - Lepers, B.
A1  - Osswald, F.
A1  - Poussot, P.
A1  - Vassilopoulos, N.
A1  - Wurtz, J.
A1  - Zeter, V.
A1  - Bielski, J.
A1  - Kozien, M.
A1  - Lacny, L.
A1  - Skoczen, B.
A1  - Szybinski, B.
A1  - Ustrycka, A.
A1  - Wroblewski, A.
A1  - Marie-Jeanne, M.
A1  - Balint, P.
A1  - Fourel, C.
A1  - Giraud, J.
A1  - Jacob, J.
A1  - Lamy, T.
A1  - Latrasse, L.
A1  - Sortais, P.
A1  - Thuillier, T.
A1  - Mitrofanov, S.
A1  - Loiselet, M.
A1  - Keutgen, Th.
A1  - Delbar, Th.
A1  - Debray, F.
A1  - Trophine, C.
A1  - Veys, S.
A1  - Daversin, C.
A1  - Zorin, V.
A1  - Izotov, I.
A1  - Skalyga, V.
A1  - Burt, G.
A1  - Dexter, A. C.
A1  - Kravchuk, V. L.
A1  - Marchi, T.
A1  - Cinausero, M.
A1  - Gramegna, F.
A1  - De Angelis, G.
A1  - Prete, G.
A1  - Collazuol, G.
A1  - Laveder, M.
A1  - Mazzocco, M.
A1  - Mezzetto, M.
A1  - Signorini, C.
A1  - Vardaci, E.
A1  - Di Nitto, A.
A1  - Brondi, A.
A1  - La Rana, G.
A1  - Migliozzi, P.
A1  - Moro, R.
A1  - Palladino, V.
A1  - Gelli, N.
A1  - Berkovits, D.
A1  - Hass, M.
A1  - Hirsh, T. Y.
A1  - Schuhmann, M.
A1  - Stahl, A.
A1  - Wehner, J.
A1  - Bross, A.
A1  - Kopp, J.
A1  - Neuffer, D.
A1  - Wands, R.
A1  - Bayes, R.
A1  - Laing, A.
A1  - Soler, P.
A1  - Agarwalla, S. K.
A1  - Cervera Villanueva, A.
A1  - Donini, A.
A1  - Ghosh, T.
A1  - Gómez Cadenas, J. J.
A1  - Hernández, P.
A1  - Martín-Albo, J.
A1  - Mena, O.
A1  - Burguet-Castell, J.
A1  - Agostino, L.
A1  - Buizza-Avanzini, M.
A1  - Marafini, M.
A1  - Patzak, T.
A1  - Tonazzo, A.
A1  - Duchesneau, D.
A1  - Mosca, L.
A1  - Bogomilov, M.
A1  - Karadzhov, Y.
A1  - Matev, R.
A1  - Tsenov, R.
A1  - Akhmedov, E.
A1  - Blennow, M.
A1  - Lindner, M.
A1  - Schwetz, T.
A1  - Fernández Martinez, E.
A1  - Maltoni, M.
A1  - Menéndez, J.
A1  - Giunti, C.
A1  - González García, M. C.
A1  - Salvado, J.
A1  - Coloma, P.
A1  - Huber, P.
A1  - Li, T.
A1  - López Pavón, J.
A1  - Orme, C.
A1  - Pascoli, S.
A1  - Meloni, D.
A1  - Tang, J.
A1  - Winter, W.
A1  - Ohlsson, T.
A1  - Zhang, H.
A1  - Scotto-Lavina, L.
A1  - Terranova, F.
A1  - Bonesini, M.
A1  - Tortora, L.
A1  - Alekou, A.
A1  - Aslaninejad, M.
A1  - Bontoiu, C.
A1  - Kurup, A.
A1  - Jenner, L. J.
A1  - Long, K.
A1  - Pasternak, J.
A1  - Pozimski, J.
A1  - Back, J. J.
A1  - Harrison, P.
A1  - Beard, K.
A1  - Bogacz, A.
A1  - Berg, J. S.
A1  - Stratakis, D.
A1  - Witte, H.
A1  - Snopok, P.
A1  - Bliss, N.
A1  - Cordwell, M.
A1  - Moss, A.
A1  - Pattalwar, S.
A1  - Apollonio, M.
T1  - High intensity neutrino oscillation facilities in Europe
JF  - Physical Review Special Topics-Accelerators and Beams
N2  - The EUROnu project has studied three possible options for future, high intensity neutrino oscillation facilities in Europe. The first is a Super Beam, in which the neutrinos come from the decay of pions created by bombarding targets with a 4 MW proton beam from the CERN High Power Superconducting Proton Linac. The far detector for this facility is the 500 kt MEMPHYS water Cherenkov, located in the Frejus tunnel. The second facility is the Neutrino Factory, in which the neutrinos come from the decay of mu(+) and mu(-) beams in a storage ring. The far detector in this case is a 100 kt magnetized iron neutrino detector at a baseline of 2000 km. The third option is a Beta Beam, in which the neutrinos come from the decay of beta emitting isotopes, in particular He-6 and Ne-18, also stored in a ring. The far detector is also the MEMPHYS detector in the Frejus tunnel. EUROnu has undertaken conceptual designs of these facilities and studied the performance of the detectors. Based on this, it has determined the physics reach of each facility, in particular for the measurement of CP violation in the lepton sector, and estimated the cost of construction. These have demonstrated that the best facility to build is the Neutrino Factory. However, if a powerful proton driver is constructed for another purpose or if the MEMPHYS detector is built for astroparticle physics, the Super Beam also becomes very attractive.
KW  - EMMA
KW  - beta-beam
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-126611
VL  - 16
IS  - 2
ER  - 
TY  - JOUR
A1  - Klement, Rainer J.
A1  - Abbasi-Senger, N.
A1  - Adebahr, S.
A1  - Alheid, H.
A1  - Allgaeuer, M.
A1  - Becker, G.
A1  - Blanck, O.
A1  - Boda-Heggemann, J.
A1  - Brunner, T.
A1  - Duma, M.
A1  - Eble, M. J.
A1  - Ernst, I.
A1  - Gerum, S.
A1  - Habermehl, D.
A1  - Hass, P.
A1  - Henkenberens, C.
A1  - Hildebrandt, G.
A1  - Imhoff, D.
A1  - Kahl, H.
A1  - Klass, N. D.
A1  - Krempien, R.
A1  - Lewitzki, V.
A1  - Lohaus, F.
A1  - Ostheimer, C.
A1  - Papachristofilou, A.
A1  - Petersen, C.
A1  - Rieber, J.
A1  - Schneider, T.
A1  - Schrade, E.
A1  - Semrau, R.
A1  - Wachter, S.
A1  - Wittig, A.
A1  - Guckenberger, M.
A1  - Andratschke, N.
T1  - The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases
JF  - BMC Cancer
N2  - Background
The aim of this analysis was to model the effect of local control (LC) on overall survival (OS) in patients treated with stereotactic body radiotherapy (SBRT) for liver or lung metastases from colorectal cancer.

Methods
The analysis is based on pooled data from two retrospective SBRT databases for pulmonary and hepatic metastases from 27 centers from Germany and Switzerland. Only patients with metastases from colorectal cancer were considered to avoid histology as a confounding factor. An illness-death model was employed to model the relationship between LC and OS.

Results
Three hundred eighty-eight patients with 500 metastatic lesions (lung n = 209, liver n = 291) were included and analyzed. Median follow-up time for local recurrence assessment was 12.1 months. Ninety-nine patients with 112 lesions experienced local failure. Seventy-one of these patients died after local failure. Median survival time was 27.9 months in all patients and 25.4 months versus 30.6 months in patients with and without local failure after SBRT. The baseline risk of death after local failure exceeds the baseline risk of death without local failure at 10 months indicating better survival with LC.

Conclusion
In CRC patients with lung or liver metastases, our findings suggest improved long-term OS by achieving metastatic disease control using SBRT in patients with a projected OS estimate of > 12 months.
KW  - colorectal cancer
KW  - illness-death model
KW  - liver metastases
KW  - lung metastases
KW  - tumor control probability
KW  - stereotactic body radiation therapy
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-325877
VL  - 19
ER  -